Circadian Therapeutics develops drugs that derive their therapeutic effects through modulation of the control of sleep and circadian rhythm
Circadian rhythms are essential for leading the human body through its daily cycle, governing a number of factors such as body temperature, cardiovascular efficiency, melatonin production, and, crucially, sleep. However, these rhythms are increasingly affected by modern life.
Already impacted by age, mental health, blindness, and a number of rare diseases, our increasing reliance on smartphones and technology, use of caffeine and alcohol, mounting numbers of air miles, and our relationship with shift work is knocking our bodies’ inner clocks dangerously out of sync.
In the short term, disrupted circadian rhythms can lead to cognitive and memory impairment, impulsiveness, and negative effects on empathy. If they remain disrupted, long term suffers may develop cardiovascular problems, type II diabetes, immunosuppression, and cancer.
The economic cost of disrupted circadian rhythms is staggering, in Europe alone costing over €100bn. Meanwhile, recent research by Rand Europe discovered that sleep deprived workers are costing the United Kingdom £40bn a year in lost productivity and absences.
Circadian Therapeutics is aiming to replace hospital-based, expensive diagnostics through the development of a home-based ambulatory electroencephalogram (EEG) device that will provide accurate and minimally intrusive measurement of brain function and circadian rhythms.
Current pharmacological treatments have fundamental limitations in addressing the scale of sleep and circadian rhythm disruption. Circadian Therapeutics has developed novel drugs that aim to fill the break, providing fast, effective, and safe treatment to patients in need.